Kathleen Idason Ms

Kathleen Idason MS, MBA has had extensive experience in regulatory affairs within the pharmaceutical industry. From 2011 to 2018, they worked at Eli Lilly and Company as the Director of Global Regulatory Affairs, focusing on CMC Biologics. In 2018, they joined Outlook Therapeutics, Inc. as the Director of Regulatory Affairs before transitioning to Rocket Pharmaceuticals in 2020 as the Director of Regulatory CMC.

Kathleen Idason MS, MBA has obtained an MS and an MBA degree from an unspecified institution. However, further details regarding the start year, end year, and specific field of study are not available.